NCT05236608View on ClinicalTrials.gov

A Study to Evaluate the Combination of Nivolumab With ADG106 in Metastatic NSCLC

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

November 12, 2021

Primary Completion Date

May 31, 2024

Study Completion Date

May 31, 2024

Conditions
Metastatic Non Small Cell Lung Cancer
Interventions
DRUG

Nivolumab

Administered together with ADG106 via intravenous infusion.

DRUG

ADG106

Administered as an intravenous infusion over 90 minutes.

Trial Locations (2)

169610

NOT_YET_RECRUITING

National Cancer Centre Singapore, Singapore

Unknown

RECRUITING

National University Hospital, Singapore

Sponsors
All Listed Sponsors
collaborator

Adagene Inc

INDUSTRY

collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Singapore Translational Cancer Consortium

UNKNOWN

lead

National University Hospital, Singapore

OTHER

NCT05236608 - A Study to Evaluate the Combination of Nivolumab With ADG106 in Metastatic NSCLC | Biotech Hunter | Biotech Hunter